Health insurance provider Elevance Health (NYSE: EVH) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 2.9% year on year to $50.18 billion. Its non-GAAP profit of $12.58 per share was 16.4% above analysts’ consensus estimates.

Is now the time to buy ELV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Elevance Health’s first quarter was shaped by disciplined execution across its core businesses, with management highlighting both favorable claims experience and pronounced seasonality in the Individual ACA segment as contributors to outperformance. CEO Gail Boudreaux pointed to early evidence of cost containment in Medicaid, improved clinical outcomes through Carelon, and a more pronounced shift toward bronze ACA plans as key factors. Management emphasized that embedding AI across workflows and proactive clinical interventions are creating measurable efficiency gains and supporting more consistent results.

Looking ahead, Elevance Health’s guidance is underpinned by continued investment in artificial intelligence, further integration of Carelon’s risk-based care models, and a strategic focus on affordability and member retention. CFO Mark Kaye noted that the company’s updated outlook assumes prudent cost management and ongoing expansion of risk-based programs. Management believes that maturing technology investments and disciplined portfolio repositioning should support at least 12% adjusted EPS growth in the following year, citing improved visibility into care trends and the impact of rate negotiations with state partners.

Key Insights from Management’s Remarks

Management credited the quarter’s outperformance to a combination of cost discipline, AI-enabled operational efficiencies, and targeted interventions in high-cost care areas.

• AI and automation gains: Elevance Health is embedding artificial intelligence across clinical, operational, and administrative workflows, resulting in lower administrative costs, earlier member interventions, and improved payment integrity. Boudreaux stated that these capabilities are “improving how we engage members and how we manage costs,” citing adoption of virtual assistants by over 22 million members and advanced provider-matching tools.

• Carelon expansion: The Carelon segment, particularly its risk-based and home-based care programs, drove clinical improvements such as a 20% reduction in hospital readmissions and over 10% savings in post-acute care. Management highlighted strong demand for Carelon’s integrated offerings, including behavioral health and specialty pharmacy, reinforcing its role as a growth driver.

• Medicaid cost containment: Targeted interventions in Medicaid, especially in behavioral health and specialty pharmacy, led to early evidence of cost reductions. Management cited predictive analytics and rigorous clinical oversight as key tools for addressing high-cost therapy utilization and substance use disorder risks.

• ACA segment optimization: A pronounced shift toward bronze-tier ACA plans improved seasonality and defers a greater portion of planned costs to the second half of the year. Management described this as a positive development for financial sustainability and retention.

• Commercial and PBM demand: The commercial group maintained pricing discipline and saw strong employer interest for integrated medical and pharmacy solutions. Carelon Rx experienced national account wins and cross-selling momentum, supported by demand for transparent, fee-based pharmacy benefit models.

Drivers of Future Performance

Management’s guidance for 2026 and beyond is driven by ongoing technology investments, evolving product mix, and the maturation of risk-based care solutions.

• AI-enabled efficiency and cost control: Continued investment in AI and automation is expected to drive further administrative cost reductions and enable earlier clinical interventions. Management sees these capabilities as foundational to sustainable expense management, improved member engagement, and long-term operating margin expansion.

• Carelon’s risk-based strategies: The company is scaling risk-based programs in oncology, behavioral health, and post-acute care through Carelon, which management expects will improve clinical outcomes and reduce admissions and emergency room visits. Successful expansion of these programs is viewed as a primary lever for future earnings growth and margin improvement.

• Medicaid and ACA membership dynamics: Management anticipates ongoing eligibility reverifications in Medicaid and a continued shift towards bronze plans in the ACA segment. The company’s outlook accounts for potential headwinds from state rate negotiations and acuity pressures, but expects improved rate alignment and targeted interventions to mitigate risks over time.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will be monitoring (1) the effectiveness and measurable outcomes of AI and automation initiatives across the enterprise, (2) progress in expanding Carelon’s risk-based care models and their impact on clinical outcomes, and (3) trends in Medicaid membership and rate negotiations with state partners. Continued execution on ACA product mix optimization and commercial client retention will also be important markers for tracking Elevance Health’s performance trajectory.

Elevance Health currently trades at $328.02, in line with $328.11 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.